DeepMind CEO Demis Hassabis

Al­pha­bet kick­starts new AI drug dis­cov­ery out­fit with lessons learned from Deep­Mind pro­tein break­throughs

Last sum­mer marked a ma­jor break­through in drug dis­cov­ery when Deep­Mind, a pre­dic­tive mod­el­ing start­up from Google par­ent com­pa­ny Al­pha­bet, of­fered the most ac­cu­rate pic­ture yet of the “pro­tein fold­ing” prob­lem. The Al­pha­bet team is now prop­ping up a unit fo­cused sole­ly on drug dis­cov­ery, and it will look to lever­age lessons learned from Deep­Mind’s ex­am­ple.

Al­pha­bet has launched Iso­mor­phic Labs, a Lon­don-based drug dis­cov­ery start­up lever­ag­ing the com­pa­ny’s AI and ma­chine learn­ing work, and lessons from Deep­Mind’s Al­phaFold break­throughs, CEO Demis Has­s­abis said in a blog post Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.